Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAPVAC-101
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
GAPVAC-101 is an actively personalized therapeutic cancer vaccine regimen developed by the Glioma Actively Personalized Vaccine Consortium (GAPVAC), led by Immatics and BioNTech, for the treatment of newly diagnosed glioblastoma. The regimen consists of two personalized peptide-based vaccines administered sequentially: APVAC1, which targets non-mutated glioblastoma-associated antigens (GAAs) selected from a pre-manufactured warehouse based on the patient's tumor expression profile and HLA-ligandome, and APVAC2, which is custom-synthesized to target patient-specific tumor neoantigens (neoepitopes) identified via next-generation sequencing. The vaccines are administered with GM-CSF and poly-ICLC as adjuvants alongside standard temozolomide chemotherapy.
- Other names
- actively personalized vaccineactively personalized vaccinesAPVACAPVAC1 + APVAC2GAPVACsynthetic glioblastoma tumor-associated peptides vaccine therapy APVAC1
02
Targets
Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on GAPVAC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAPVAC-101.